With a market capitalization (market cap) of $4.14B — a measure of how much the company is worth — Tango Therapeutics, Inc. is the 1565th most valuable company in Healthcare as of August 18, 2026. Shares trade at $25.44, up +0.59% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Visit websiteAs of August 18, 2026, Tango Therapeutics, Inc. (TNGX) is worth $4.14B — this is its market capitalization, the total value of all its outstanding shares.
Tango Therapeutics, Inc.’s market cap is $4.14B, which ranks it #1565 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Tango Therapeutics, Inc. (TNGX) shares trade at $25.44, up 0.59% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025